MIAMI, FL -- (MARKET WIRE) -- March 26, 2007 -- DOR BioPharma, Inc. (OTCBB: DORB) (“DOR” or the “Company”) announced that it has received clearance from the U.S. Food and Drug Administration (“FDA”) to conduct a Phase 2 clinical trial of orBec® for the prevention of Graft-versus-Host disease (“GVHD”).
